Full metadata record

DC FieldValueLanguage
dc.contributor.author김종오ko
dc.contributor.author트란탄힙ko
dc.contributor.author티르거네쉬라마사미ko
dc.contributor.author트롱두이히유ko
dc.contributor.author신범수[신범수]ko
dc.contributor.author최한곤[최한곤]ko
dc.contributor.author용철순ko
dc.date.accessioned2015-12-17T04:07:09Z-
dc.date.available2015-12-17T04:07:09Z-
dc.date.created2015-11-13-
dc.date.issued201408-
dc.identifier.citationPHARMACEUTICAL RESEARCH, v.31, no.8, pp.1978 - 1988-
dc.identifier.issn0724-8741-
dc.identifier.urihttp://hdl.handle.net/YU.REPOSITORY/31340-
dc.identifier.urihttp://dx.doi.org/10.1007/s11095-014-1300-z-
dc.description.abstractTo investigate whether delivery of a histone deacetylase inhibitor, vorinostat (VOR), by using solid lipid nanoparticles (SLNs) enhanced its bioavailability and effects on multidrug-resistant cancer cells. VOR-loaded SLNs (VOR-SLNs) were prepared by hot homogenization using an emulsification-sonication technique, and the formulation parameters were optimized. The cytotoxicity of the optimized formulation was evaluated in cancer cell lines (MCF-7, A549, and MDA-MB-231), and pharmacokinetic parameters were examined following oral and intravenous (IV) administration to rats. VOR-SLNs were spherical, with a narrowly distributed average size of similar to 100 nm, and were physically stable for 3 months. Drug release showed a typical bi-phasic pattern in vitro, and was independent of pH. VOR-SLNs were more cytotoxic than the free drug in both sensitive (MCF-7 and A549) and resistant (MDA-MB-231) cancer cells. Importantly, SLN formulations showed prominent cytotoxicity in MDA-MB-231 cells at low doses, suggesting an ability to effectively counter the P-glycoprotein-related drug efflux pumps. Pharmacokinetic studies clearly demonstrated that VOR-SLNs markedly improved VOR plasma circulation time and decreased its elimination rate constant. The areas under the VOR concentration-time curve produced by oral and IV administration of VOR-SLNs were significantly greater than those produced by free drug administration. These in vivo results clearly highlighted the remarkable potential of SLNs to augment the bioavailability of VOR. VOR-SLNs successfully enhanced the oral bioavailability, circulation half-life, and chemotherapeutic potential of VOR.-
dc.language영어-
dc.publisherSPRINGER/PLENUM PUBLISHERS-
dc.subjectHISTONE DEACETYLASE INHIBITORS-
dc.subjectSUBEROYLANILIDE HYDROXAMIC ACID-
dc.subjectANTICANCER DRUG-DELIVERY-
dc.subjectTRANS-RETINOIC ACID-
dc.subjectPHYSICOCHEMICAL CHARACTERIZATION-
dc.subjectIMPROVE ENCAPSULATION-
dc.subjectANTITUMOR-ACTIVITY-
dc.subjectFORMULATION-
dc.subjectCARRIERS-
dc.subjectDOCETAXEL-
dc.titleDevelopment of Vorinostat-Loaded Solid Lipid Nanoparticles to Enhance Pharmacokinetics and Efficacy against Multidrug-Resistant Cancer Cells-
dc.typeArticle-
dc.identifier.wosid000341712400011-
dc.identifier.scopusid2-s2.0-84925599104-
Appears in Collections:
약학대학 > 약학부 > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE